trial

The Use of Selective Estrogen Receptor Modulators in the Treatment of Schizophrenia- a Pilot Study

NCTId NCT00206557
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 60
Sponsored by The Alfred
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
60
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2002-10
Primary completion
—
Eligibility
FEMALE · 45 Years · 70 Years

Interventions & indications

Drugs
RaloxifeneEstradiol/dyhydroprogestrone

Sponsors

The AlfredLead Sponsor
Stanley Medical Research InstituteCollaborator

Investigators

1
Jayashri Kulkarni, MBBS, MPM, FRANZCP, PHDPrincipal Investigator

Sites

1 total
Melbourne, Australia

Facts & assertions

3 sourced
Enrollment
60
Phase
PHASE2
Status
COMPLETED
relationships
The graph out of here
drug
Raloxifene
drug
Estradiol/dyhydroprogestrone
drug
lead_sponsor
The Alfred
company
collaborator
Stanley Medical Research Institute
company
indication
Schizophreniform Disorder
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication
investigator
Jayashri Kulkarni, MBBS, MPM, FRANZCP, PHD
person